These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report. Kumar AK; Dakhil C; Teeka Satyan M; Haideri N J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389 [TBL] [Abstract][Full Text] [Related]
3. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma. Grannis CH; Dewan VN; Wang RC Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. Federico V; Breccia M; Petrucci MT; Loglisci G; Mansueto G; Mercanti C; Levi A; Cartoni C; Musto P; Alimena G Clin Adv Hematol Oncol; 2012 Apr; 10(4):266-8. PubMed ID: 22706491 [No Abstract] [Full Text] [Related]
5. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses. Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020 [TBL] [Abstract][Full Text] [Related]
6. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380 [TBL] [Abstract][Full Text] [Related]
7. Bortezomib in multiple myeloma. Vandenbroucke JP; Kroep JR N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272 [No Abstract] [Full Text] [Related]
9. A striking response to bortezomib in a patient with pleural localization of multiple myeloma. Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298 [No Abstract] [Full Text] [Related]
10. Myeloma: diagnosis complications and supportive care. Morgan G Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795 [TBL] [Abstract][Full Text] [Related]
11. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Mauermann ML; Blumenreich MS; Dispenzieri A; Staff NP Muscle Nerve; 2012 Dec; 46(6):970-7. PubMed ID: 23225391 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease. Siniscalchi A; Dentamaro T; Perrotti A; Tatangelo P; de Fabritiis P; Caravita T Ann Hematol; 2010 Aug; 89(8):821-2. PubMed ID: 19953253 [No Abstract] [Full Text] [Related]
13. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait. Badros A; Gahres N Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432 [No Abstract] [Full Text] [Related]
14. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695 [TBL] [Abstract][Full Text] [Related]
15. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography. Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250 [TBL] [Abstract][Full Text] [Related]
16. [Current perspectives in the treatment of multiple myeloma - news and views]. Knop S Dtsch Med Wochenschr; 2012 Mar; 137(13):636-9. PubMed ID: 22434170 [No Abstract] [Full Text] [Related]
17. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib for myeloma -- much ado about something. Dispenzieri A N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811 [No Abstract] [Full Text] [Related]
19. Effects of bortezomib on bone disease in multiple myeloma. Drake MT; Rajkumar SV Am J Hematol; 2009 Jan; 84(1):1-2. PubMed ID: 19030185 [No Abstract] [Full Text] [Related]